|
Canada-0-MILLWORK 회사 디렉토리
|
회사 뉴스 :
- Lupin Ltd. Faces Short-Term Challenges Amidst Strong Long-Term Growth . . .
Lupin Ltd faced a notable decline on June 17, 2025, closing at Rs 1936 6, underperforming its sector The stock is trading below key moving averages, indicating a bearish trend Despite recent struggles, Lupin's long-term performance has significantly outpaced the broader market over the past three years
- Lupin FY2025 Results - Lupin
Lupin FY2025 Results Mumbai, May 14, 2025: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2025 These audited results were taken on record by the Board of Directors at a meeting held today
- Lupin Ltd (LUPIN) Share Price Target 2024, 2025, upto 2030 - Dailybulls
By the end of 2025, the price target for Lupin Ltd is expected to potentially reach ₹2,533 97, considering bullish market trends As per technical data, the minimum share price target of LUPIN is expected to reach Rs 2634 27 and the maximum value that shares of LUPIN can reach is Rs 3263 92
- Lupin Q4 Results 2025 - Find Lupin Q4 Earnings Result | LUPIN Q4 . . . - Mint
Lupin Q4 Results BSE: 500257; NSE: LUPIN; ISIN: INE326A01037; Sector: Biotechnology Drugs
- LUPIN LIMITED
During the quarter ended June 30, 2024 and year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9 0 million (~ 750 5 million} in connection with the drug Glumetza® without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation
- LUPIN LTD. : Latest Quarterly Results Analysis - ICICI Direct
Pharmaceuticals company Lupin announced Q4FY25 FY25 results Q4FY25 Financial Highlights: Gross Profit was Rs 38,760 million compared to Rs 33,213 million in Q4FY24, with a gross margin of 69 7% Personnel cost was 18 0% of sales at Rs 10,013 million compared to Rs 9,002 million in Q4FY24
- Lupin (NSE:LUPIN) Stock Price Overview - Stock Analysis
Get the latest Lupin Limited (NSE:LUPIN) stock price with financials, statistics, dividends, charts and more
- Lupin : June 7, 2025 Lupin Receives Tentative Approval from U. S. FDA . . .
Mumbai, Naples, June 7, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U S FDA) for its Abbreviated New Drug Application for Oxcarbazepine Extended-Release (ER) Tablets, 150 mg, 300 mg, and 600 mg This product would be manufactured at
- Reports Filings - Lupin
Generic business carve out – Lupin Life Sciences Limited (LLSL) Letter rec’d regarding input tax credit Patna depot Appointment of Chief Technical Officer
- Live LUPIN 2300 CE (CALL) 26 June 2025 options price chart analysis . . .
Lot size of LUPIN Lupin Limited is 425 Total Open Interest for CALL (CE) of strike 2300 is 37,400 Munafa analysis LUPIN 2300 CE might not be profitable for buyers to buy this CALL, but this could be a good opportunity for sellers to make a quick profit
|
|